Cover Image
Market Research Report

Digital Pharma: Are We Nearly There?

Published by Datamonitor Healthcare Product code 858260
Published Content info 38 Pages
Delivery time: 1-2 business days
Price
Back to Top
Digital Pharma: Are We Nearly There?
Published: August 14, 2018 Content info: 38 Pages
Description

Overview

Digital's potential to transform every aspect of the pharmaceutical value chain, from discovery to commercial, is widely documented. This analysis explores how far along pharma is in its shift to digital, and where digital is having the greatest impact - both on patients and the bottom line.

As technology firms wade into healthcare, and as regulators begin to approve "digital therapeutics," there is an urgency behind pharma's digital transformation. Pharmaceutical firms are engaging in different ways, and at different speeds. They are bringing in new skills, new systems, and new structures in order to capture the benefits of digital.

Many of these benefits are around process efficiency and research and development (R&D) productivity - and clinical development in particular. That is where most money and time are spent in the traditional R&D process, and thus where improvements are most visible.

Consumer-facing digital healthcare products, though much talked-about, are not currently influencing pharma's bottom line. Instead, they are changing the way healthcare is delivered. These changes will influence pharma's role within the healthcare system and its relationship with customers.

Culture is one of the biggest challenges that pharma companies face as they go digital. Digital must become a core capability, not a standalone function. Yet it comes with faster innovation cycles, plus new kinds of expertise and partnerships that threaten traditional hierarchies and demand a fresh mindset.

Table of Contents
Product Code: DMKC0195978

TABLE OF CONTENTS

OVERVIEW

THE DIGITAL IMPERATIVE

  • How is pharma "going digital"?
  • Bibliography

DIGITAL'S IMPACT ALONG THE VALUE CHAIN

  • Digital is impacting everything, especially clinical development
  • Verily's Baseline: setting the digital health reference data
  • Regulators talk digital
  • Bibliography

DIGITAL PARTNERSHIPS

  • A partnering chess game
  • Partnerships are changing the pharma R&D model
  • Bibliography

LESSONS LEARNED

  • Digital is transformational
  • Digital is not a department, it is a core capability
  • Culture is the hardest part
  • Talent integration must be thoughtful
  • Financial returns are indirect
  • Staying analog is not an option
  • Bibliography

APPENDIX

  • About the author
  • Scope
  • Methodology

LIST OF FIGURES

  • Figure 1: The degree of digital impact at different stages of the pharma value chain
  • Figure 2: Digital-Pharma deals: tie-ups between Big/mid-sized pharma and digital health firms

LIST OF TABLES

  • Table 1: Selected pharma approaches to "going digital"
  • Table 2: Selected pharma-AI discovery deals
  • Table 3: Selected digital collaborations across a range of areas and partner types
  • Table 4: Lessons from pharma's digital journey to date
Back to Top